On December 4, 2025, Insulet Corporation announced that it had received FDA 510(k) clearance for a series of major enhancements to its flagship automated insulin-delivery platform, Omnipod 5. The regulatory milestone marks one of the most significant product upgrades since the system’s initial launch in 2022 and underscores Insulet’s continued investment in algorithm-driven diabetes-management technology.
The newly cleared improvements focus on strengthening both user control and automated insulin-delivery efficiency. These advances are designed to serve the growing population of individuals seeking tighter glucose-management targets without increasing their risk of hypoglycemia. As automated insulin-delivery systems become more deeply integrated into everyday care, the Omnipod 5 update reflects a broader industry trend toward personalization, safety, and clinical intelligence.
What the Update Includes
A central feature of the enhancement package is the introduction of a new 100 mg/dL Target Glucose option. Previously, users could not select a target lower than 110 mg/dL, making this adjustment especially meaningful for those who benefit from a tighter glycemic range. With the update, the system now offers six selectable targets between 100 and 150 mg/dL, spaced in 10 mg/dL increments. This expanded range allows clinicians and users to align the device’s automated dosing behavior more closely with individualized treatment plans.
Beyond the new target settings, Insulet has refined the system’s core algorithm to minimize disruptions in Automated Mode. Users may now experience fewer instances where the system disengages due to prolonged periods of high glucose. By maintaining automation more consistently, the upgraded algorithm aims to support improved time-in-range outcomes while helping reduce the cognitive burden associated with manual insulin adjustments. Early real-world data suggests that lowering the glucose target can raise time-in-range percentages without a notable increase in time spent below range, an important factor in maintaining safety.
Who Can Use It and When
The enhanced version of Omnipod 5 retains its regulatory clearance for individuals aged 2 years and older with type 1 diabetes and for adults with type 2 diabetes. This means the upgrade remains accessible to the broad user base already eligible for the system. Insulet has indicated that the updated features will begin rolling out across the United States during the first half of 2026, giving clinicians, diabetes educators, and users time to prepare for the new capabilities.
Why It Matters
For both patients and healthcare providers, the clearance represents meaningful progress toward more adaptive and user-friendly insulin-delivery solutions. The ability to target a lower glucose range offers greater customization for those who benefit from a more aggressive therapeutic approach. At the same time, improved automation reduces the likelihood of interruptions that can complicate daily diabetes management. For Insulet, the enhancements reinforce its leadership position in tubeless automated insulin-delivery technology, an increasingly competitive landscape within the global diabetes-care market.
What’s Next for Insulet
Looking ahead, Insulet has indicated ongoing efforts to expand the Omnipod ecosystem through next-generation hardware, deeper integration with continuous glucose-monitoring technologies, and advanced data-analytics tools. The newly cleared algorithm may serve as a foundation for future product developments, encouraging broader adoption while setting the stage for new clinical capabilities in coming years.
